Purpose
Compliant version of the Child and Adolescent Immunization Schedule by Age
Birth to 15 Months
< < Back to Child & Adolescent Immunization Schedule
¶ = Range of recommended ages for all children
†= Range of recommended ages for catch-up immunization
§ = Range of recommended ages for certain high-risk groups
# = Recommended vaccination can begin in this age group
± = Recommended vaccination based on shared clinical decision-making
• = No recommendation/Not applicable
| Vaccine and other immunizing agents | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Respiratory syncytial virus  (RSV-mAb [Nirsevimab]) |
1 dose depending on maternal RSV vaccination status, See notes¶ | ¶ | ¶ | § | 1 dose (8 through 19 months), See notes§ | ||||||
| Hepatitis B (HepB) |
1st dose¶ | ←2nd dose→¶ | † | ←3rd dose→¶ | |||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
• | 1st dose¶ | 2nd dose¶ | See notes¶ | • | ||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) |
• | 1st dose¶ | 2nd dose¶ | 3rd dose¶ | † | ←4th dose→¶ | |||||
| Haemophilus influenzae type b (Hib) |
• | 1st dose¶ | 2nd dose¶ | See notes¶ | † | ←3rd or 4th dose, See notes→¶ |
|||||
| Pneumococcal conjugate (PCV15, PCV20) |
• | 1st dose¶ | 2nd dose¶ | 3rd dose¶ | † | ←4th dose→¶ | |||||
| Inactivated poliovirus (IPV: <18 yrs) |
• | 1st dose¶ | 2nd dose¶ | ←3rd dose→¶ | |||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
• | 1 or more doses of updated (2023–2024 Formula) vaccine (See notes)¶ |
|||||||||
| Influenza (IIV4) |
• | Annual vaccination 1 or 2 doses¶ | |||||||||
 Influenza (LAIV4) |
• | ||||||||||
| Measles, mumps, rubella (MMR) |
• | See notes§ | ←1st dose→¶ | ||||||||
| Varicella (VAR) |
• | ←1st dose→¶ | |||||||||
| Hepatitis A (HepA) |
• | See notes§ | ←2-dose series, See notes→¶ | ||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) |
• | ||||||||||
| Human papillomavirus (HPV) |
• | ||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
• | See notes§ | |||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) |
• | ||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) |
• | ||||||||||
| Dengue (DEN4CYD: 9-16 yrs) |
• | ||||||||||
| Mpox |
• | ||||||||||
18 Months to 18 Years
| Vaccine and other immunizing agents | 18 mos |
19-23 mos |
2-3 yrs |
4-6 yrs |
7-10 yrs |
11-12 yrs |
13-15 yrs |
16 yrs |
17-18 yrs |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus (RSV-mAb [Nirsevimab]) |
1 dose (8 through 19 months), See notes§ | § | • | • | • | • | |||||||||||||||||
| Hepatitis B (HepB) |
←3rd dose→¶ | † | |||||||||||||||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
• | ||||||||||||||||||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) |
←4th dose→¶ | † | 5th dose¶ | • | |||||||||||||||||||
| Haemophilus influenzae type b (Hib) |
† | † | § | § | |||||||||||||||||||
| Pneumococcal conjugate (PCV15, PCV20) |
† | † | § | § | |||||||||||||||||||
| Inactivated poliovirus (IPV: <18 yrs) |
←3rd dose→¶ | † | 4th dose¶ | † | † | † | See notes• |
||||||||||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
1 or more doses of updated (2023–2024 Formula) vaccine (See notes)¶ |
||||||||||||||||||||||
| Influenza (IIV4) |
Annual vaccination 1 or 2 doses¶ | ¶ | ¶ | ¶ | ¶ | Annual vaccination 1 dose only¶ | |||||||||||||||||
Influenza (LAIV4) |
• | Annual vaccination 1 or 2 doses¶ | OR ¶ |
¶ | Annual vaccination 1 dose only¶ | ||||||||||||||||||
| Measles, mumps, rubella (MMR) |
† | 2nd dose¶ | † | ||||||||||||||||||||
| Varicella (VAR) |
† | 2nd dose¶ | † | ||||||||||||||||||||
| Hepatitis A (HepA) |
← 2-dose series, See notes→¶ | † | |||||||||||||||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) |
• | † | 1 dose¶ | § | |||||||||||||||||||
| † | |||||||||||||||||||||||
| Human papillomavirus (HPV) |
• | § | See notes¶ | † | |||||||||||||||||||
| # | |||||||||||||||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
See notes§ | 1st dose¶ | † | 2nd dose¶ | † | ||||||||||||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) |
• | • | • | • | • | § | See notes§ | ||||||||||||||||
| • | • | ± | |||||||||||||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) |
• | Seasonal administration during pregnancy, See notes§ |
|||||||||||||||||||||
| Dengue (DEN4CYD: 9-16 yrs) |
• | • | • | ¶ | Seropositive in endemic dengue areas (See notes)¶ |
• | |||||||||||||||||
| Mpox |
• | § | |||||||||||||||||||||
Content Source:
National Center for Immunization and Respiratory Diseases